AAAAAA

   
Results: 1-12 |
Results: 12
SAFETY TOLERABILITY TRIAL OF SDZ ENA-713 IN PATIENTS WITH PROBABLE ALZHEIMERS-DISEASE
Authors: SRAMEK JJ ANAND R WARDLE TS IRWIN P HARTMAN RD CUTLER NR
Citation: Jj. Sramek et al., SAFETY TOLERABILITY TRIAL OF SDZ ENA-713 IN PATIENTS WITH PROBABLE ALZHEIMERS-DISEASE, Life sciences, 58(15), 1996, pp. 1201-1207
ORTHOSTASIS IN ALZHEIMER-DISEASE - A RETROSPECTIVE ANALYSIS
Authors: JHEE SS SRAMEK JJ WARDLE TS CUTLER NR
Citation: Ss. Jhee et al., ORTHOSTASIS IN ALZHEIMER-DISEASE - A RETROSPECTIVE ANALYSIS, Alzheimer disease and associated disorders, 9(4), 1995, pp. 243-246
EFFECTS OF THE CHOLINOMIMETIC SDZ ENS-163 ON SCOPOLAMINE-INDUCED COGNITIVE IMPAIRMENT IN HUMANS
Authors: BRASS EP POLINSKY R SRAMEK JJ MOORE M JONES D VEROFF AE WARDLE TS CUTLER NR
Citation: Ep. Brass et al., EFFECTS OF THE CHOLINOMIMETIC SDZ ENS-163 ON SCOPOLAMINE-INDUCED COGNITIVE IMPAIRMENT IN HUMANS, Journal of clinical psychopharmacology, 15(1), 1995, pp. 58-62
THE SAFETY AND TOLERANCE OF XANOMELINE TARTRATE IN PATIENTS WITH ALZHEIMERS-DISEASE
Authors: SRAMEK JJ HURLEY DJ WARDLE TS SATTERWHITE JH HOURANI J DIES F CUTLER NR
Citation: Jj. Sramek et al., THE SAFETY AND TOLERANCE OF XANOMELINE TARTRATE IN PATIENTS WITH ALZHEIMERS-DISEASE, Journal of clinical pharmacology, 35(8), 1995, pp. 800-806
ACETYLCHOLINESTERASE INHIBITION BY ZIFROSILONE - PHARMACOKINETICS ANDPHARMACODYNAMICS
Authors: CUTLER NR SEIFERT RD SCHLEMAN MM SRAMEK JJ SZYLLEYKO OJ HOWARD DR BARCHOWSKY A WARDLE TS BRASS EP
Citation: Nr. Cutler et al., ACETYLCHOLINESTERASE INHIBITION BY ZIFROSILONE - PHARMACOKINETICS ANDPHARMACODYNAMICS, Clinical pharmacology and therapeutics, 58(1), 1995, pp. 54-61
THE SAFETY AND TOLERANCE OF XANOMELINE TARTRATE, AN M1-SPECIFIC CHOLINERGIC AGONIST, IN PATIENTS WITH ALZHEIMERS-DISEASE
Authors: CUTLER NR SRAMEK JJ SEIFERT RD CONRAD JJ WARDLE TS DIES F HURLEY DJ THOREN LM
Citation: Nr. Cutler et al., THE SAFETY AND TOLERANCE OF XANOMELINE TARTRATE, AN M1-SPECIFIC CHOLINERGIC AGONIST, IN PATIENTS WITH ALZHEIMERS-DISEASE, Neurobiology of aging, 15, 1994, pp. 190000104-190000104
THE SAFETY AND TOLERANCE OF XANOMELINE TARTRATE, A M(1)-SPECIFIC CHOLINERGIC AGONIST, IN PATIENTS WITH ALZHEIMERS-DISEASE
Authors: SRAMEK JJ CUTLER NR SEIFERT RD CONRAD JJ WARDLE TS HURLEY DJ THOREN LM
Citation: Jj. Sramek et al., THE SAFETY AND TOLERANCE OF XANOMELINE TARTRATE, A M(1)-SPECIFIC CHOLINERGIC AGONIST, IN PATIENTS WITH ALZHEIMERS-DISEASE, Clinical pharmacology and therapeutics, 55(2), 1994, pp. 174-174
A BRIDGING STUDY OF XANOMELINE TARTRATE IN ALZHEIMERS-DISEASE (AD)
Authors: CUTLER NR SRAMEK JJ SEIFERT RD CONRAD JJ WARDLE TS HURLEY DJ THOREN LM
Citation: Nr. Cutler et al., A BRIDGING STUDY OF XANOMELINE TARTRATE IN ALZHEIMERS-DISEASE (AD), Biological psychiatry, 35(9), 1994, pp. 628-628
MAXIMALLY TOLERATED DOSE OF THE MUSCARINIC AGONIST CI-979 IN ALZHEIMERS-DISEASE (AD)
Authors: CUTLER NR SRAMEK JJ SEIFERT RD HOURANI J REECE PA BOCKBRADER H SEDMAN AJ WARDLE TS
Citation: Nr. Cutler et al., MAXIMALLY TOLERATED DOSE OF THE MUSCARINIC AGONIST CI-979 IN ALZHEIMERS-DISEASE (AD), Biological psychiatry, 35(9), 1994, pp. 628-628
EFFECTS OF THE NOVEL CHOLINOMIMETIC SDZ-ENS-163 ON SCOPOLAMINE-INDUCED COGNITIVE IMPAIRMENT
Authors: CUTLER NR POLINSKY R SEIFERT RD SRAMEK JJ MOORE M WARDLE TS JONES DC
Citation: Nr. Cutler et al., EFFECTS OF THE NOVEL CHOLINOMIMETIC SDZ-ENS-163 ON SCOPOLAMINE-INDUCED COGNITIVE IMPAIRMENT, Biological psychiatry, 35(9), 1994, pp. 641-641
SAFETY, TOLERANCE, PHARMACOKINETIC AND RBC CHOLINESTERASE ACTIVITY OFMDL-73,745
Authors: CUTLER NR SEIFERT RD SRAMEK JJ SCHLEMAN MM WARDLE TS HOURANI J
Citation: Nr. Cutler et al., SAFETY, TOLERANCE, PHARMACOKINETIC AND RBC CHOLINESTERASE ACTIVITY OFMDL-73,745, Biological psychiatry, 35(9), 1994, pp. 680-680
THE SAFETY AND EFFICACY OF IPSAPIRONE VS LORAZEPAM IN OUTPATIENTS WITH GENERALIZED ANXIETY DISORDER (GAD) - SINGLE-SITE FINDINGS FROM A MULTICENTER TRIAL
Authors: CUTLER NR SRAMEK JJ WARDLE TS HESSELINK JMK ROESCHEN JK
Citation: Nr. Cutler et al., THE SAFETY AND EFFICACY OF IPSAPIRONE VS LORAZEPAM IN OUTPATIENTS WITH GENERALIZED ANXIETY DISORDER (GAD) - SINGLE-SITE FINDINGS FROM A MULTICENTER TRIAL, Psychopharmacology bulletin, 29(2), 1993, pp. 303-308
Risultati: 1-12 |